Marksans Pharma has reported a robust start to fiscal year 2027, with Q1 revenue climbing 35.6% year-on-year to INR 841 crores. The company achieved its highest-ever quarterly EBITDA of INR 213 crores and PAT of INR 159 crores. Growth was driven by strong performance in Europe, up 74.7%, and North America, up 15.1%, bolstered by recent acquisitions and organic expansion.
Marksans Pharma Reports Strong Q1 FY27 Performance
Marksans Pharma announced a significant upswing in its financial performance for the first quarter of fiscal year 2027 (Q1 FY27), concluding on June 30, 2026. The company posted a consolidated revenue of INR 840.8 crores, marking a substantial 35.6% increase compared to INR 620 crores in Q1 FY26. This growth trajectory underscores the effectiveness of the company’s strategic investments in product development, manufacturing, and international presence.
Key Financial Highlights
The quarter was distinguished by record profitability. Marksans Pharma achieved its highest-ever quarterly EBITDA, reaching INR 213 crores, a remarkable 112.8% year-on-year growth. The EBITDA margin expanded to 25.3% from 16.1% in the prior year. Net profit after tax (PAT) also saw a significant surge, standing at INR 159.4 crores, up 173.9% from INR 58.2 crores in Q1 FY26. PAT margin improved to 18.4%.
Geographical Performance Drivers
Europe emerged as a strategic growth engine, with revenue from the UK and Europe combined reaching INR 356 crores, an impressive 74.7% year-on-year increase. This growth was significantly boosted by the acquisition of QliniQ B.V. in the Netherlands, which contributed approximately INR 44 crores to the quarter’s revenue. Even without this contribution, the region saw a 53.1% organic growth. The company also announced the acquisition of ABCnow GmbH in Germany, with consolidation commencing from Q2 FY27.
North America remained the largest market, contributing INR 377 crores, a 15.1% year-on-year rise, accounting for about 45% of consolidated revenue. In Australia and New Zealand, revenue grew by 53.7% year-on-year to INR 88 crores, reflecting seasonal patterns and underlying business strength.
Strategic Outlook and Capital Allocation
Marksans Pharma expressed confidence in sustaining momentum, focusing on scaling operations across geographies, accelerating new product launches, and strengthening its European market presence. The company highlighted its disciplined approach to capital allocation, prioritizing inorganic opportunities that promise scalability and resilience. With a healthy cash balance of approximately INR 1,058 crores, Marksans Pharma is actively exploring further acquisitions to fuel its growth strategy, particularly within Europe.
Operational and Manufacturing Updates
The company reported that its Goa unit 2, including the Teva facility, is progressing well, currently generating over INR 50 crores in revenue and operating at 60%-65% capacity. Management is exploring opportunities for manufacturing capacity expansion, considering both greenfield and brownfield projects, with a focus on acquiring assets at favorable valuations over the next one to two years.
Source: BSE
